CFTR Modulators Show Functional Microbiota Shifts in Cystic Fibrosis

A study published in Archivos de bronconeumologia investigates the impact of CFTR modulator therapy on the microbiota of cystic fibrosis (CF) patients. The research focuses on the functional and compositional changes in the gut and lung microbiota after one year of treatment with elexacaftor-tezacaftor-ivacaftor (ETI), a combination therapy that has significantly improved clinical outcomes for CF patients.

Study Design and Methods

Researchers conducted a 12-month prospective study involving 35 clinically stable CF patients who were beginning ETI therapy. The study collected paired fecal and sputum samples at the start and after 12 months of treatment. These samples were analyzed using shotgun metagenomics, metaproteomics, and short-chain fatty acid (SCFA) quantification. The multi-omics data were then integrated with clinical parameters assessing lung, hepatic, pancreatic, and intestinal function.

The study aimed to understand the effects of ETI on the microbiota, particularly focusing on functional changes, as the compositional effects were expected to be minimal. The researchers looked at microbial diversity and the presence of specific microbial proteins and pathways.

Key Findings

The study found that ETI therapy led to significant clinical improvements, such as increased ppFEV₁, higher fecal elastase levels, and better nutritional status. However, major lung pathogens persisted, and changes in liver or intestinal inflammation markers were minimal.

In terms of microbiota composition, the study observed limited shifts. Alpha diversity remained stable, and changes in beta diversity accounted for only a small variance in both the gut and lung microbiomes. Notably, butyrate-producing genera were enriched in feces, while oropharyngeal taxa increased in sputum samples.

Metaproteomics revealed a broad downregulation of host neutrophil-driven inflammatory proteins, with sputum samples showing increased abundance of extracellular matrix-related proteins. Microbial proteins linked to carbohydrate and lipid metabolism, particularly butanoate pathways, increased in feces, alongside a trend for higher butyrate levels. In sputum, there was an increase in formaldehyde dehydrogenase enzymes, indicating enhanced oxidative microbial metabolism.

Implications and Limitations

The findings suggest that while ETI therapy is associated with minimal compositional changes in the microbiota, it induces substantial functional reprogramming. This includes an increase in butyrate-producing taxa, attenuation of host pro-inflammatory pathways, and a shift in lung metabolism toward oxidation. These changes indicate a less inflammatory and more stable host-microbiota ecosystem, despite ongoing pathogenic colonization.

However, the study has limitations. The sample size of 35 patients is relatively small, which may affect the generalizability of the findings. Additionally, the study's observational nature means it can demonstrate associations but not causation. Further research is needed to explore the long-term effects of ETI therapy on the microbiota and its clinical implications.

For more insights into the role of short-chain fatty acids in the microbiome, you might find our article on short-chain fatty acids informative.